Transcription of Issue 153 December 2021 HIGHLIGHTS
{{id}} {{{paragraph}}}
Example: dental hygienist
Issue 153 December 2021 HIGHLIGHTS
Key to symbols used Orphan medicine Generic medicine Biosimilar medicine Conditional approval Exceptional circumstances 153 Key information for patients, consumers and healthcare professionals Published monthly by the European Medicines Agency An agency of the European Union HUMAN MEDICINES HIGHLIGHTS Issue 153 December 2021 This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency. Information is selected based on recommendations from consulted patients, consumers and healthcare professionals, and does not necessarily cover all relevant information published by the Agency.
• Flynpovi (eflornithine / sulindac) Intended for the treatment of familial adenomatous polyposis, a hereditary disease in which polyps (growths) form in the gut Haematology (blood conditions) Positive CHMP opinions on new medicines • Tavneos (avacopan)
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: